Drug Channels

MAY 30, 2023

P.S. Join my more than 41,000 LinkedIn followers for daily links to neat stuff.

Hospitals 75

Hospitals Biosimilars 75

Drug Channels

SEPTEMBER 13, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements.

Biosimilars 97

Biosimilars Hospitals 97

Drug Channels

OCTOBER 27, 2021

It’s the biosimilar boom! Scream as Blue Cross Blue Shield frightfully overpays hospitals Shocking! So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! Brrr.did you hear that? Believe it or not, U.S

Biosimilars 75

Biosimilars Hospitals Independent Pharmacies Drug Pricing 75

pharmaphorum

OCTOBER 1, 2020

Adalimumab – sold by AbbVie as Humira as well as in biosimilar form by companies including Novartis’ Sandoz unit, Amgen and Biogen/Samsung joint venture Bioepis – will be used in the phase 2 AVID-CC study to see if it can prevent progression to respiratory failure in people with coronavirus infections.

Biosimilars 90

Biosimilars Hospitals Inpatient 90

Drug Channels

DECEMBER 12, 2022

These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial healthcare costs and expand 340B, and the need for complex new processes to administer the IRA's lower pharmacy reimbursements.

Biosimilars 98

Biosimilars Hospitals 98

Pharmaceutical Commerce

MAY 13, 2024

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

Biosimilars 52

Biosimilars Hospitals 52

Drug Channels

SEPTEMBER 28, 2021

Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 Autumn is here! You can also find me on LinkedIn , where I have more than 20,000 followers.

Drug Pricing 81

Drug Pricing Hospitals Biosimilars 81

Drug Channels

JUNE 27, 2021

on generic and biosimilar trends Some hospitals seem to be gaming their 340B eligibility Plus, tips on effective hospital marketing. As you declare your vaccinated independence, celebrate with these Drug Channels fireworks: Amazon’s teeny step toward pharmacy disruption How patients view copay accumulators My $0.02

Hospitals 52

Hospitals Biosimilars Vaccines 52

Big Molecule Watch

DECEMBER 26, 2023

announced the successful completion of the transition of the acquired biosimilars business in approximately 120 countries, a year ahead of schedule. The post Biosimilar Deals Updates: Biocon, AstraZeneca appeared first on Big Molecule Watch. As an update to our previous report , Biocon Biologics Ltd. (a a subsidiary of Biocon Ltd.)

Biosimilars 64

Biosimilars Vaccines Hospitals 64

STAT

DECEMBER 14, 2022

During the height of the Covid-19 pandemic, supply chain breakdowns and export restrictions made it difficult, if not impossible, for hospitals to import crucial materials, from N95 masks to life-saving drugs. China, which then accounted for more than 85% of all U.S.

Hospitals 246

Hospitals Biosimilars 246

Drug Channels

JULY 27, 2021

In this issue: The top 10 stingiest hospitals Medicare Part B's savings from biosimilars What happened to hepatitis C drug costs and rebates? Let’s cut through the summer haze with our refreshing breeze of articles and insights. Costco beats Medicare Part D Plus, math madness with Duke’s Fuqua business school.

Biosimilars 52

Biosimilars Hospitals Drug Pricing 52

pharmaphorum

NOVEMBER 25, 2020

This is supported by the company’s portfolio of other approved medicines and revenues from its Sandoz biosimilars and generics division. Uptake of biosimilars in the US has been better than hoped, perhaps aided by hospitals focusing on cost because COVID-19 has curtailed income from surgery.

Biosimilars 119

Biosimilars Hospitals 119

Pharmaceutical Business Review

JUNE 16, 2023

Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries by 2030. It features crucial challenges that bar patients from gaining access to biosimilar medicines.

Biosimilars 59

Biosimilars Hospitals 59

Pharmaceutical Business Review

MAY 25, 2023

Under the partnership, the biosimilars will be developed and supplied by Alvotech while Advanz Pharma will be responsible for registration and marketing in Europe. Alvotech and Advanz’s agreement includes proposed biosimilars to Entyvio (vedolizumab) and Simponi (golimumab).

Biosimilars 52

Biosimilars Hospitals 52

FDA Law Blog: Biosimilars

MAY 16, 2024

Houck — Employee diversion of controlled substances from hospitals has been an issue since at least 1986 when I became a diversion investigator with the Drug Enforcement Administration (“DEA”). The Kentucky hospital resolved the allegations for $4,394,600 and entered into a three-year MOA in November 2021.

Controlled Substances 59

Controlled Substances Hospitals Intravenous Solutions 59

pharmaphorum

OCTOBER 27, 2020

Meanwhile, global biosimilar revenues jumped 80% to $424 million, driven by recent oncology biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) in global markets. Pfizer also announced that is cutting three drugs from its pipeline.

Biosimilars 104

Biosimilars Vaccines Hospitals Compounding 104

Pharma Leaders

JUNE 16, 2023

Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines. Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries by 2030.

Biosimilars 52

Biosimilars Hospitals 52

Express Pharma

JANUARY 3, 2025

Investing in cutting-edge research, particularly in biosimilars, novel biologics, and cell and gene therapies, will be crucial. However, there are very few biopharma players who have made a mark globally with respect to biosimilars. Indian players are still in the early stage of growth within the biosimilars segment.

Biosimilars 105

Biosimilars Vaccines Hospitals Drug Development 105

RX Note

DECEMBER 25, 2024

Introduction Consumers from private hospitals and clinics are provided with a huge range of brand choices , being it original or generic brand. However, with the proliferation of biosimilars and liposomal or pegylated forms, health care professionals are now encouraged to communicate using product name for certain circumstances (e.g.

Biosimilars 52

Biosimilars Community Pharmacies Labelling Communication 52

PharmaShots

APRIL 5, 2023

neovascular (wet) AMD Additionally, the availability of Byooviz could enable more patients to access this type of vision-saving therapy as it brings a sustainable and cost-effective anti-VEGF treatment to Canadian vision care Byooviz was approved in Canada for the treatment of multiple eye disorders.

Biosimilars 49

Biosimilars Packaging Labelling Hospitals 49

Big Molecule Watch

NOVEMBER 7, 2024

CT-P41, Celltrion’s biosimilar of Amgen’s PROLIA, is scheduled to launch in Korea in the first half of 2025. Under the agreement, Daewoong and Celltrion will jointly promote CT-P41 at Korean general hospitals and clinics. The post Daewoong and Celltrion to Market Denosumab Biosimilar in Korea appeared first on Big Molecule Watch.

Biosimilars 40

Biosimilars Hospitals 40

FDA Law Blog: Biosimilars

FEBRUARY 11, 2025

Houck One of the most significant issues facing hospitals and other facilities is the diversion of controlled substances meant for patients by physicians, pharmacists, nurses and other trusted healthcare employees. Employee diversion can also result in unwanted local and national publicity.

Controlled Substances 59

Controlled Substances Hospitals 59

Drug Channels

MAY 27, 2020

Before you venture outside for your lockdown barbeque, check out these noteworthy items off the Drug Channels grill: Payers predict how COVID-19 will affect formularies Our analysis of the 2020 retail-to-mail shift AmerisourceBergen profiles biosimilars Plus, CVS pharmacy offers a clever way to measure appropriate social distancing.

Biosimilars 52

Biosimilars Specialty Pharmacies Hospitals 52

PharmaShots

MAY 24, 2023

Shots: Advanz Pharma gets an exclusive right from Alvotech to commercialize five proposed biosimilars in the EU. proposed biosimilars to Simponi, Entyvio & 3 additional early-stage undisclosed biosimilar candidates. Your go-to media platform for customized news ranging for multiple indications.

Biosimilars 40

Biosimilars Hospitals 40

European Pharmaceutical Review

APRIL 30, 2024

CHMP biosimilar recommendations A positive opinion for Tofidence (tocilizumab) was adopted by the committee, indicated for rheumatoid arthritis, COVID-19, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Biosimilars 98

Biosimilars Generic Medicine Chemotherapy Hospitals 98

PharmaShots

FEBRUARY 1, 2023

Ximluci is expected to be available in the UK in 2023 The approval for Ximluci was granted through the EC decision reliance procedure, whereby the MHRA’s decision was based on the EC Ximluci was approved in the UK for wet AMD, DME, diabetic retinopathy, RVO, and visual impairment due to choroidal neovascularization in adults.

Biosimilars 40

Biosimilars Packaging Diabetes Hospitals 40

Drug Channels

SEPTEMBER 8, 2021

As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data.

Drug Pricing 97

Drug Pricing Biosimilars Hospitals 97

FDA Law Blog: Biosimilars

SEPTEMBER 12, 2023

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Controlled Substances 49

Controlled Substances Hospitals 49

Drug Channels

NOVEMBER 9, 2022

Fein will share his latest thinking on a wide range of topics, including: Retail and specialty pharmacy trends Vertical integration and consolidation The Inflation Reduction Act of 2022 The Medicare Part D Redesign Biosimilars Discount cards and cash-pay pharmacies The growing impact of hospitals and health systems The 340B Drug Pricing Program Federal (..)

Specialty Pharmacies 98

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 98

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more.

Drug Pricing 75

Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more.

Drug Pricing 74

Drug Pricing Biosimilars Hospitals 74

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2023

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Controlled Substances 45

Controlled Substances Hospitals 45

Drug Channels

NOVEMBER 22, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

Drug Channels

OCTOBER 11, 2022

Drug Distribution Industry Expands as COVID-19 Disruption Fades and Biosimilars Boom (press release) We’re offering special discounted pricing if you order before October 21, 2022! contains new data on hospital acquisitions and consolidation activity. pharmaceutical distribution industry. Section 6.1.6.

Biosimilars 74

Biosimilars Hospitals Pharmaceutical Manufacturing Documentation 74

Drug Channels

JULY 30, 2024

GoodRx joins the Humira biosimilar price war with Boehringer Ingelheim Averon revealed to be a new buying group for biosimilars for CVS Health and Cardinal Health Why the IRA will be bad news for 340B hospitals Plus, the June 2024 update to my all-time favorite chart. Did the FTC’s compelling interim report prove its case?

Biosimilars 40

Biosimilars Hospitals 40